Strongyloides Hyperinfection — Steroid-Triggered Dissemination & Ivermectin

Key Points

• Strongyloides can persist for decades because of autoinfection.
• Corticosteroids are a major trigger for hyperinfection.
• Hyperinfection commonly causes severe pulmonary and GI disease.
• Recurrent gram-negative bacteremia or meningitis can result from bacterial translocation carried by migrating larvae.
• Eosinophilia may disappear in severe hyperinfection and does not exclude the diagnosis.
• Serial stool testing improves sensitivity; sputum/BAL can be diagnostic in hyperinfection.
• Ivermectin is first-line therapy.
• Severe disease requires daily ivermectin until parasitologic clearance is sustained.

Algorithm

1. Identify epidemiologic risk before planned corticosteroids or major immunosuppression.
2. Screen at-risk patients with Strongyloides serology and/or stool testing when time permits.
3. In a deteriorating immunosuppressed patient, look for GI symptoms, pulmonary infiltrates, sepsis, and unexplained gram-negative bacteremia.
4. Send stool and respiratory specimens for larvae; do not wait for all results if hyperinfection is strongly suspected.
5. Start ivermectin 200 micrograms/kg daily for hyperinfection/dissemination.
6. Reduce immunosuppression when feasible and assess drug absorption if ileus is present.
7. Treat bacterial sepsis/meningitis and provide organ support.
8. Continue ivermectin until stool/sputum examinations remain negative for 2 weeks.

Clinical Synopsis & Reasoning

Strongyloides stercoralis is unusual among helminths because autoinfection allows the parasite to persist for decades after the original exposure. Chronic infection may be asymptomatic or cause intermittent abdominal pain, diarrhea, rash, or eosinophilia. Larva currens—a rapidly moving serpiginous urticarial rash, often on the buttocks or trunk—is a characteristic clue.

The high-stakes problem is hyperinfection syndrome. Corticosteroids are the classic trigger, but other immunosuppressive states, HTLV-1 infection, transplantation, malignancy, and severe illness can increase risk. Accelerated autoinfection produces a massive increase in larval burden through the GI tract and lungs. Patients develop abdominal pain, ileus, GI bleeding, cough, wheeze, diffuse pulmonary infiltrates, hypoxemia, or respiratory failure.

As larvae migrate across the bowel wall they can carry enteric bacteria into the bloodstream, causing recurrent gram-negative bacteremia, sepsis, or meningitis. This association is a crucial diagnostic clue. Eosinophilia, common in chronic infection, may disappear during hyperinfection and should not be used to exclude the diagnosis.

Diagnosis can be made by detecting larvae in stool, sputum, BAL fluid, or other specimens. Serial stool examinations improve sensitivity because a single specimen can miss chronic infection. Serology is useful for screening chronic infection but can be less reliable in immunosuppressed patients and does not prove hyperinfection by itself. In severe disease, larvae are often abundant in respiratory and stool samples.

The reasoning priority is prevention. Before starting high-dose corticosteroids or other potent immunosuppression in a patient with epidemiologic risk—especially prior residence in endemic tropical/subtropical areas—screen for Strongyloides when time permits. A patient who deteriorates after steroids with pulmonary/GI disease and unexplained gram-negative sepsis should be treated as possible hyperinfection immediately.

Treatment Strategy & Disposition

Ivermectin is first-line therapy. For uncomplicated chronic infection, standard oral therapy is typically 200 micrograms/kg daily for 1–2 days, with follow-up testing in patients with persistent symptoms or positive stool studies. Hyperinfection and disseminated strongyloidiasis require ivermectin 200 micrograms/kg daily until stool and/or sputum examinations remain negative for at least 2 weeks.

Reduce or stop immunosuppressive therapy when clinically possible, especially corticosteroids. Patients with ileus or malabsorption may not absorb oral ivermectin reliably. Rectal administration has been described, and in extreme circumstances investigational subcutaneous veterinary ivermectin has been used under regulatory mechanisms when enteral routes are impossible.

Treat bacterial complications aggressively. Gram-negative bacteremia, sepsis, meningitis, pneumonia, and other translocation-related infections require appropriate antimicrobial therapy and source evaluation. Respiratory failure may require mechanical ventilation; GI bleeding or ileus requires standard supportive management.

Hyperinfection is an ICU-level disease when respiratory failure, sepsis, shock, or CNS involvement is present. Mortality can be extraordinarily high, which is why screening before immunosuppression is so important. Patients with chronic infection should be counseled that apparently remote travel or residence can remain clinically relevant decades later.

Epidemiology / Risk Factors

• Strongyloides is endemic in tropical and subtropical regions and occurs focally elsewhere.
• Chronic infection can persist lifelong without treatment.
• Risk is increased in patients exposed to corticosteroids, HTLV-1, transplantation, or other immunosuppression.
• Hyperinfection mortality is very high when diagnosis is delayed.

Investigations

When to Screen Before Immunosuppression

Pharmacology

Prognosis / Complications

• Uncomplicated chronic infection is usually curable with ivermectin.
• Hyperinfection/dissemination can have mortality approaching catastrophic levels, especially with sepsis or respiratory failure.
• Outcome improves with early ivermectin, reduced immunosuppression, and aggressive treatment of bacterial complications.
• Relapse is possible if parasitologic clearance is incomplete or immune suppression persists.

Patient Education / Counseling

• Tell patients that Strongyloides can remain in the body for decades after exposure.
• Advise patients with known or prior Strongyloides infection to tell clinicians before receiving steroids or chemotherapy.
• Explain why follow-up stool testing may be needed after treatment.
• Seek urgent care for respiratory symptoms, severe abdominal symptoms, fever, or confusion during immunosuppression.
• Discuss travel/residence history openly because it can directly change preventive care.

Notes

Strongyloides is a prevention-first infection. Chronic infection can be nearly silent, but corticosteroids can transform it into an overwhelming autoinfective syndrome with respiratory failure and enteric bacteremia. That is why exposure history before immunosuppression is not trivia—it can be lifesaving.

The classic board-level trap is eosinophilia. Eosinophilia may suggest chronic infection, but severe hyperinfection can occur with no eosinophilia at all. In a steroid-treated patient with pulmonary infiltrates, abdominal disease, and gram-negative sepsis, the absence of eosinophils should never end the evaluation.

References

1. CDC — Clinical Care of Strongyloides — Link
2. CDC — Clinical Overview of Strongyloides (2026) — Link